TRAF2 Mouse anti-Human, Clone: 33A1293, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA141028
Suggested positive control: Hela whole cell extract, antigen standard for TRAF2 (transient overexpression lysate).Tumor necrosis factor (TNF) induced signaling is mediated through association of TNF receptor (TNFR) with adaptor proteins, such as TNF receptor associated proteins (TRAFs). TRAFs form a family of cytoplasmic adapter proteins that mediate signal transduction from many members of the TNF-receptor superfamily (e.g. RANK, CD30, CD40, etc.) and the interleukin-1 receptor. The carboxy-terminal region of TRAFs is required for self-association and interaction with receptor cytoplasmic domains following ligand-induced oligomerization. Recent molecular cloning studies have lead to identification of six TRAFs (TRAF1-TRAF6) (1-4). TRAF2 is a 502-amino acid protein. Mutagenic studies suggest that the N-terminal RING finger and two adjacent zinc fingers of TRAF2 are required for NF-kB activation, where as interaction with TNFR is mediated through C-terminus domain (5,6). Distinct domains in the N- and -C termini are also required for association with TRAF1 and protein kinase receptor interacting protein (RIP). TRAF2 is involved in cellular resistant to TNF-induced apoptosis. TRAF-2 deficient mice appeared normal at birth, however, they die prematurely, probably due to atrophy of thymus, spleen, muscle mass and lack of TRAF-2 ft.s cytoprotective role.
|PBS with 0.05% BSA and 0.05% sodium azide|
|MGC:45012, TRAP, TRAP3|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Immunohistochemistry (Paraffin), Western Blot|
|Fusion protein corresponding to residues 205-222 of human TRAF2.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok